Introduction
It is established now that endogenous peptides with opioid activity appear to modulate gonado¬ trophin secretion in several species, essentially exerting a suppressive effect. For example, adminis¬ tration of met-enkephalin has been shown to decrease serum luteinizing hormone (LH) (Bruni, Van Vugt, Marshall efe Meites, 1977) . Also, naloxone stimulated LH secretion at some ages in immature female rats (Blank, Panerai & Friesen, 1979) . In cyclic women, naloxone treatment increased both plasma LH concentration and the frequency of LH pulses (Ropert, Quigley & Yen, 1981) and infusion of the met-enkephalin analogue D-Ala2MePhe4Met(o)enkephalin-ol (FK33-824) into post-menopausal women significantly reduced plasma LH concentrations (Grossman et al, 1981) . Furthermore, Quigley & Yen (1980) have shown that the extent of LH modulation by opioid peptides may vary throughout the menstrual cycle since the human female responds rapidly to naloxone in terms of LH secretion during the mid-luteal phase of the cycle, but not during the early follicular phase. There is evidence for some species that such changes in sensitivity to naloxone are related to the steroid milieu at the time of administration, because gonadectomized rats became refractory to naloxone and the opioid analogue FK33-824, an effect which was reversed after steroid hormone priming (Bhanot & Wilkinson, 1983a , 1984 . Hypothalamohypophysial portal blood concentrations of ß-endorphin, an index of hypothalamic opioid activity, were reduced in the ovariectomized monkey whilst oestradiol replacement therapy partly restored the levels and oestrogen therapy combined with progesterone was more effective . Opiates do not alter the LH responses to GnRH in the monkey and human (Grossman et al, 1981; Ferin, Wehrenberg, Lam, Alston & Vande Wiele, 1982) , indicating that they exert their actions at a site other than the pituitary, possibly the hypothalamus or in neurones that impinge on the hypothalamus (Drouva, Epelbaum, Tapia-Arancibia, Laplante & Kordon, 1981; Lakoski & Gebhart, 1981) .
There is no information on the effects of opioids on reproductive function in the ewe, a species of particular interest in this respect since gonadotrophin secretion is naturally suppressed during seasonal anoestrus, an effect thought to be related to changes in sensitivity to steroid feedback (Legan & Karsch, 1980 Oestrous cycle studies Experiment 1. To study the effects of naloxone upon tonic LH release during the follicular phase of the cycle, it was necessary to work between the time progesterone falls to basal levels and the onset of the preovulatory LH surge. This period occupies about 37 h in the natural situation and is some 8 h shorter when induced, due to the more rapid decline in plasma progesterone after exogenous progesterone withdrawal compared to that during the natural cycle (Haresign, 1985) . To 25 or 50 mg (2 ml)/h; equivalent to~0 -27, 0-55 and 1-10 mg/kg h"1 (2 sheep/dose, with the same dose given to the same animal on each occasion).
Hormone assays
Plasma LH concentration was measured by the specific double-antibody radioimmunoassay as described by McLeod, Haresign & Lamming (1982) . Sensitivity, defined as 2 s.d. from the binding value at zero concentration of LH was 0-3 ng NIH-LH-S23 equiv./ml plasma. Intra-and inter¬ assay coefficients of variation within this study were 7-9% and 8-1 % respectively. Progesterone was measured by the method of Haresign, Foster, Haynes, Crighton & Lamming (1975) . The limit of sensitivity was 01 ng/ml plasma and intra-and inter-assay coefficients of variation were < 12%.
Statistical analysis
An LH episode was defined as a rise in plasma concentration of the hormone greater than 50% Episode frequency/12 h 900(6-11)'' 6-75(3-9)" 500 (4-6)b
Mean LH episode amplitude (ng/ml) Tables 1 and 2. Analysis of deviance using a Poisson distribution was used io compare discrete data that did not conform to a normal distribution, i.e. episode frequency (Neider & Wedderburn, 1972 Martin, 1984) occurred in one ewe about 40 h after FK33-824 treatment and this animal subsequently showed plasma progesterone concentrations indicative of ovulation and the formation of a normal corpus luteum (Fig. 2 Although not statistically significant, it appeared that the mean LH concentrations remained elevated for a longer period in the sheep treated with naloxone alone compared with those given FK33-824 + naloxone (see Fig. 1 ). Mean LH concentration, episode frequency and episode height were significantly reduced between treatment and run-off but not between control and run-off periods. In all ewes treated with naloxone alone a preovulatory LH surge occurred, a corpus luteum was present at laparoscopy and progesterone secretion appeared normal in the subsequent cycles. Fig. 3 (1 of the 6 sheep used in the early and mid-luteal phase experiment was subsequently found, to be pregnant and is excluded). There were no significant effects of dose, and no differences between treatments carried out in the early and mid-luteal phase so these data have been combined and are summarized in Table 2 .
Naloxone treatment resulted in a significant (P < 001) increase in mean LH concentration and number of LH episodes in these groups compared to the control and run-off periods. There were no significant differences in peak height between any periods. For the late luteal group different animals had to be used and it is for this reason that the data are not combined with those from the early and mid-luteal phases. In this group, there were trends indicative of an effect of naloxone although these did not reach significance (Table 2) . Progesterone data for this study confirmed that the animals were in the stated part of the cycle.
Studies during seasonal anoestrus Experiment 3. Progesterone determinations in all animals were below the sensitivity of the assay, indicating the absence of active luteal tissue and that the animals were anovulatory. There were no discernible large follicles or corpora lutea at laparoscopy.
LH profiles for yearlings treated with naloxone during early, mid-and late anoestrus are shown in Fig. 4 , and those for mature ewes during the same periods in Fig. 5 . Data from both types of sheep are summarized in Table 3 . For the yearlings naloxone treatment resulted in significant (P < 001 or < 005) increases in mean LH concentration, episode frequency and episode height during late anoestrus, only episode frequency (P < 005) at mid-anoestrus and had no effect on any measure during early anoestrus. Data for the pre-treatment and post-treatment periods were not significantly different, indicating that any effect of naloxone was short-lived.
It is evident (see Fig. 4 Infusion of the long-acting met-enkephalin analogue FK33-824 blocked pulsatile LH secretion during the follicular phase of the oestrous cycle. When naloxone was administered concurrently, the effect of FK33-824 was removed, as demonstrated by the presence of LH pulses (with a fre¬ quency somewhat lower but amplitude higher than in the control period) and a tendency towards higher mean LH concentrations during treatment compared with the control period. This suggests that the effect of FK33-824 is mediated specifically through opioid receptors, primarily to depress LH episode frequency through an action on the neurogenic pulse generator system (Jackson, 1977; Peet & Lincoln, 1977; Kalra & Simpkins, 1981) . Furthermore, the tendency towards an increase in LH concentration during the combined treatment results from a significant increase at the begin¬ ning of treatment which gradually declined during the treatment period (see Fig. 1 and 'Results' ). This suggests a degree of endogenous opioid suppression of LH during the follicular phase of the cycle, with the initial action of naloxone being to remove both the effect of the endogenous opioid and the exogenous drug; ultimately the action of naloxone at the dose used would be overridden by a build up of FK33-824. This possibility of endogenous opioid action during the follicular phase is given further support by the significant increase in LH concentrations and pulse frequency found over the whole treatment period when naloxone alone was administered. These observations, together with the stimulatory action of naloxone during the luteal phase, suggest that endogenous opioid peptides may exert a modulating effect on LH in the cyclic ewe and are essentially suppressive; in this respect the ewe accords with other species, namely the rat, human and monkey (Bruni et al., 1977; Ropert era/., 1981; Fermera/., 1982) .
Subtle changes in LH secretion before the ovulatory surge in the ewe are of paramount import¬ ance in the development of optimum follicular growth and subsequent luteal function (McLeod et al, 1982 (McLeod et al, , 1983 and cyclic changes in opioid action may therefore have an important role in maintaining normal cyclic activity in sheep. This is supported by the observation that infusion of FK.33-824 prevented the formation of a normal corpus luteum for the duration of at least one cycle in 3 out of 4 ewes, presumably due to the lack of a preovulatory LH surge and hence lack of ovula¬ tion. There is good evidence that morphine administration on the afternoon of pro-oestrus will block ovulation in the rat (Barraclough & Sawyer, 1955; Pang, Zimmermann & Sawyer, 1977) , an effect mediated via a suppression of the pro-oestrous surge of GnRH (Ching, 1983) . If the situation in the sheep is similar, it would seem that, since FK33-824 blocks both pulsatile LH secretion and the preovulatory LH surge, this represents either a general inhibitory effect of FK33-824 upon GnRH release or a specific effect on two distinct neural mechanisms.
These findings do differ, however, from those with women in which, during the early follicular phase, naloxone was ineffective, suggesting no endogenous opioid activity at this time. Naloxone enhanced LH secretion during the luteal phase in sheep and humans (Quigley & Yen, 1980; Ropert et al, 1981) with the response appearing somewhat more pronounced in the latter. The implication from the human studies is that a progesterone and/or oestrogen milieu may be necessary for opioid action and the difference between the species may be because of the short follicular phase in the sheep, which ovulâtes about 48 h after the cyclic demise of the corpus luteum. To make sure the experimental animals were in the follicular phase, treatment began only 18 h after removal of the progestagen-secreting sponge and there may well be some residual receptor-bound progestagen at this time.
The ewe studies also differ from those of the human (but not rats and hamsters) with respect to the systemically administered dose of naloxone apparently necessary to block the effects of opioids upon LH since the amounts given to ewes were 6-20-fold higher on a weight basis than the human dose and the response produced was less dramatic. Also, Schanbacher (1985) (Illius et al, 1983) .
The necessity to use such high levels of naloxone also raises the question as to whether the observed effects are a result of some non-specific action of the drug. We cannot answer this directly. However, we have also carried out experiments using a new opioid antagonist WIN 44441-3 (Sterling Winthrop; Ward, Pierson & Michne, 1983) which has structural similarities to naloxone. Again, high doses were needed to produce results equivalent to those reported for naloxone. The readily available ( + )-enantiomer of WIN 44441-3 had no effect upon LH concentrations, provid¬ ing evidence that for WIN 44441-3 the effect upon LH secretion is specifically mediated through opioid receptors (Brooks, Haynes & Lamming, 1986) .
It is apparent that naloxone treatment, although inducing a significant increase in LH secretion overall, resulted in a variable increase between animals particularly in luteal-phase studies (Fig. 3) . Similar There is considerable evidence that an elevated progesterone environment is required for nalox¬ one to be effective in stimulating LH secretion. For instance, during the early follicular phase in women, when plasma concentrations of this steroid are basal, naloxone is ineffective in raising plasma levels of LH (Quigley & Yen, 1980; Blankstein, Reyes, Winter & Faiman, 1981; Snowden, Khan-Dawood & Dawood, 1984) . However, maximum responses to naloxone are achieved during the luteal phase of the cycle (Quigley & Yen, 1980) . This is supported by studies which demon¬ strated that treatment of the ovariectomized monkey with a progesterone/oestrogen combination resulted in a marked increase in ß-endorphin concentrations in hypothalamic portal vein blood (Wardlaw, Wehrenberg, Ferin, Autunes & Frantz, 1982 Our data are in agreement with recent findings for the hamster in which short-days (non- breeding season) remove the otherwise good response to naloxone seen during long days (Eskes, Wilkinson & Bhanot, 1984) . This is currently the only evidence which directly supports the findings here that, in mature ewes, naloxone loses its ability to stimulate LH secretion during seasonal anoestrus. On the other hand, the yearling animals behaved differently and naloxone treatment caused significant elevations in LH secretion. The response, moreover, was apparently greater at mid-and late anoestrus than in the early anoestrous period so these animals apparently do not require any recent progesterone priming. We currently have no explanation for the difference. Because of the variability in increase of LH release between yearling sheep, it may be that the year¬ lings are in an age-related transition state between response and non-response, particularly since age has been reported to have a marked influence upon the response of other species to naloxone. For instance, naloxone treatment reversed the short photoperiod-induced suppression of LH in prepubertal and young post-pubertal (5-6 months old) hamsters, but was ineffective in reproductively more mature animals 1 year of age (Chen, Targovnik, McMillan & Randall, 1984) . Also, in the rat naloxone-induced LH increases have been shown to be greatest in the prepubertal female rat, but to diminish as the animal reaches adulthood (Blank et al, 1979) . Furthermore, administration inhibited LH secretion in gonadectomized prepubertal female rats and the response showed an age-related decline (Wilkinson & Bhanot, 1982; Bhanot & Wilkinson, 1983b ).
As stated above, the lack of an LH response to naloxone in mature ewes may be due to a non-opioid inhibitory neuronal system which is activated during seasonal anoestrus. If activation of this system was also age-dependent this would explain the ability of naloxone to stimulate LH secretion in some yearling ewes when only an opioid system is operating, but not in mature ewes when the opioid-independent pathway is activated. Furthermore the yearling ewes have an elevated LH pulse frequency compared with that of the mature ewes during the control periods, an observation which could also be explained by such a mechanism.
In conclusion, evidence is presented in support of the theory that opioids play a part in the control of LH secretion in the cyclic ewe. However, we have been unable to demonstrate that endo¬ genous opioids have major physiological significance in the seasonally induced suppression of LH secretion in the mature ewe. Nevertheless, the results presented for yearling sheep add to the current evidence that changes in the magnitude of opioid action may play a physiological role in the
